ArticleVeterinary world2020
Multidrug-resistant strains of
Article in Veterinary world, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- The Burden and Genetic Diversity of Mycobacterium bovis Infection in Humans in the Middle East and North Africa: A Systematic Review and Meta-Analysis.Transboundary and emerging diseases · 2026Pooled it
- Molecular Characterization of theAntibiotics (Basel, Switzerland) · 2026Article
- Epidemiological Survey and Economic Impact of Ruminant Tuberculosis-like Lesions at Slaughterhouses in Two Areas of Northern Algeria (2019-2024): A One Health Assessment.Pathogens (Basel, Switzerland) · 2026Article
- A bovine pulmosphere model and multiomics reveal early host response signature in tuberculosis.Communications biology · 2025Article
- Genetic diversity and antibiotic resistance ofFrontiers in cellular and infection microbiology · 2025Article
- Synthesis, characterization, andFrontiers in pharmacology · 2025Article
- Review
- Zoonotic Tuberculosis: A Neglected Disease in the Middle East and North Africa (MENA) Region.Diseases (Basel, Switzerland) · 2023Review
- Review on Bovine Tuberculosis: An Emerging Disease Associated with Multidrug-ResistantPathogens (Basel, Switzerland) · 2022Review
- Comparative diagnosis of bovine tuberculosis using single intradermal cervical tuberculin technique, conventional methods, enzyme-linked immunosorbent assay, and the gamma-interferon assay.Veterinary world · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMATERIALS AND
methodsA total of 1464 samples from cattle (1285 raw milk and 179 lymph node), and 149 human sputum samples, were collected from farms and abattoirs in Delta Egypt. Conventional methods (culture and Ziehl-Neelsen staining) were implemented as were RT-PCR using
resultsThe MBTC detection rate using the culture method was higher than for Ziehl-Neelsen staining; raw cow milk (2.56 vs. 1.63%), lymph nodes (51.59 vs. 48.04%), and human sputum (5.36 vs. 4.02%). A total of 135 isolates were obtained. Application of RT-PCR detected 138 isolates from the same set of samples. MBTC isolates were resistant to first-line antituberculosis drugs, such as pyrazinamide, isoniazid, rifampicin, and ethambutol by 78.5, 59.3, 40.7, and 31.8%, respectively, and could be highly resistant to kanamycin (82.3%) and amikacin (80.7%). However, isolates remained sensitive to ciprofloxacin (71.1%) and clarithromycin (73.3%) as second-line drugs.
conclusionThere is a growing risk for isolation of MDR-TB from raw milk and lymph nodes of field tuberculin positive cattle as well as sputum of veterinarians and workers existed in farms and abattoirs. PCR-based techniques have become the gold standard for the identification of mycobacterial species, showing high efficiency compared to bacteriological and microscopic examination. Application of the first- and second-line antituberculosis drugs in combination could counter the MDR-TB concern once infections are identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.